The results showed that high expression of DNAJC3 could enhance the sensitivity of tumor cells to cardiac glycosides (such as digoxin and ouabain) and kinase inhibitors (such as neratinib and bosutinib), while reducing the sensitivity of tumor cells to MEK inhibitors (such as PD-98059, RO-4987655, ARRY-162, selumetinib, pimasertib, and TAK-733) (Fig. 6). This evidence concerns the gene DNAJC3 and neoplasm.